1 / 7

Terbium-161 for PSMA-Targeted Radionuclide Therapy of Prostate Cancer

Explore Terbium-161, a promising isotope for PSMA-targeted radionuclide therapy in prostate cancer. This innovative treatment offers enhanced precision and efficacy, targeting cancer cells while minimizing side effects on healthy tissues.

Nuclearmedicinetherapy
Download Presentation

Terbium-161 for PSMA-Targeted Radionuclide Therapy of Prostate Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Nuclear Medicine Centre FMRi Gurugram INDIA Dr. Ishita B Sen Terbium-161 for PSMA-Targeted Radionuclide Therapy of Prostate Cancer www.nuclearmedicinetherapy.in

  2. What is Terbium-161? • A promising radioisotope for targeted radionuclide therapy (TRT). • Emits both beta and gamma radiation, ideal for therapeutic and diagnostic purposes. • Suitable for small metastases and residual cancer cells due to high precision.

  3. Benefits of Terbium-161 in PSMA Therapy • High tissue penetration with reduced damage to surrounding healthy tissue. • Enhanced efficacy in targeting prostate-specific membrane antigen (PSMA). • Longer shelf life compared to existing isotopes like Lu-177.

  4. Terbium-161 vs. Other Isotopes • Terbium-161: Superior for micrometastases due to Auger electrons. • Lutetium-177: Commonly used but less effective for small tumor cells. • Actinium-225: Effective but poses supply and handling challenges.

  5. Current Research and Applications • Clinical trials show promising results in prostate cancer patients. • Increasing interest in combining Terbium-161 with PSMA-ligands. • Potential to improve survival rates and reduce side effects.

  6. Conclusion and Future Prospects • Terbium-161 offers a revolutionary advancement in TRT for prostate cancer. • Ongoing research could expand its applications beyond PSMA therapy. • Future focus: Making it widely available and cost-effective for global use.

  7. For more information talk to Dr. Ishita B Sen today. dr.ishitasen@nuclearmedicinetherapy.in +91 8700 668 431 www.nuclearmedicinetherapy.in

More Related